This Complement 3 Glomerulopathy - Pipeline Insight, 2021 provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Complement 3 Glomerulopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Complement 3 glomerulopathy (C3G) is a rare kidney disease that has two forms: dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). Each is caused by genetic or acquired problems in controlling the body's complement system, which helps fight infections. Genetic problems can be inherited or not inherited. The acquired complications arise during a person's life. C3G can have a major impact on a person's health. The signs and symptoms of DDD tend to appear earlier than those of C3GN (usually in adolescence). However, the signs and symptoms of either form of C3G may not begin until adulthood. People with C3G often have symptoms which are related to problems with the kidney and other parts of the body.
Complement 3 Glomerulopathy - Pipeline Insight, 2021 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Complement 3 Glomerulopathy pipeline landscape is provided which includes the disease overview and Complement 3 Glomerulopathy treatment guidelines. The assessment part of the report embraces, in depth Complement 3 Glomerulopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Complement 3 Glomerulopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Complement 3 Glomerulopathy R&D. The therapies under development are focused on novel approaches to treat/improve Complement 3 Glomerulopathy.
This segment of the Complement 3 Glomerulopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Avacopan: Novartis Pharmaceuticals
Avacopan is an orally-administered drug candidate that inhibits the complement C5a receptor, or C5aR, and is being developed for inflammatory and autoimmune diseases. Avacopan blocks the activity of complement C5a, a component of the complement system and the natural ligand for C5aR. It is in phase II stage of development to treat C3 Glomerulopathy
LNP 023: Novartis Pharmaceuticals
Iptacopan is an investigational, first-in-class, orally administered factor B inhibitor of the alternative complement pathway, targeting one of the key drivers of these diseases9-11. It has the potential to become the first targeted therapy to delay progression to dialysis in C3G. It is in phase II stage of development to treat C3 Glomerulopathy
There are approx. 3+ key companies which are developing the therapies for Complement 3 Glomerulopathy. The companies which have their Complement 3 Glomerulopathy drug candidates in the most advanced stage, i.e. phase II include, Novartis.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Complement 3 Glomerulopathy therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Complement 3 Glomerulopathy drugs.
Geography Covered
- Global coverage
Complement 3 Glomerulopathy Understanding
Complement 3 Glomerulopathy: Overview
Complement 3 glomerulopathy (C3G) is a rare kidney disease that has two forms: dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). Each is caused by genetic or acquired problems in controlling the body's complement system, which helps fight infections. Genetic problems can be inherited or not inherited. The acquired complications arise during a person's life. C3G can have a major impact on a person's health. The signs and symptoms of DDD tend to appear earlier than those of C3GN (usually in adolescence). However, the signs and symptoms of either form of C3G may not begin until adulthood. People with C3G often have symptoms which are related to problems with the kidney and other parts of the body.
Complement 3 Glomerulopathy - Pipeline Insight, 2021 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Complement 3 Glomerulopathy pipeline landscape is provided which includes the disease overview and Complement 3 Glomerulopathy treatment guidelines. The assessment part of the report embraces, in depth Complement 3 Glomerulopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Complement 3 Glomerulopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Complement 3 Glomerulopathy R&D. The therapies under development are focused on novel approaches to treat/improve Complement 3 Glomerulopathy.
Complement 3 Glomerulopathy Emerging Drugs Chapters
This segment of the Complement 3 Glomerulopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Complement 3 Glomerulopathy Emerging Drugs
Avacopan: Novartis Pharmaceuticals
Avacopan is an orally-administered drug candidate that inhibits the complement C5a receptor, or C5aR, and is being developed for inflammatory and autoimmune diseases. Avacopan blocks the activity of complement C5a, a component of the complement system and the natural ligand for C5aR. It is in phase II stage of development to treat C3 Glomerulopathy
LNP 023: Novartis Pharmaceuticals
Iptacopan is an investigational, first-in-class, orally administered factor B inhibitor of the alternative complement pathway, targeting one of the key drivers of these diseases9-11. It has the potential to become the first targeted therapy to delay progression to dialysis in C3G. It is in phase II stage of development to treat C3 Glomerulopathy
Complement 3 Glomerulopathy: Therapeutic Assessment
This segment of the report provides insights about the different Complement 3 Glomerulopathy drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Complement 3 Glomerulopathy
There are approx. 3+ key companies which are developing the therapies for Complement 3 Glomerulopathy. The companies which have their Complement 3 Glomerulopathy drug candidates in the most advanced stage, i.e. phase II include, Novartis.
Phases
This report covers around 3+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Complement 3 Glomerulopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Complement 3 Glomerulopathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Complement 3 Glomerulopathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Complement 3 Glomerulopathy drugs.
Complement 3 Glomerulopathy Report Insights
- Complement 3 Glomerulopathy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Complement 3 Glomerulopathy Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Complement 3 Glomerulopathy drugs?
- How many Complement 3 Glomerulopathy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Complement 3 Glomerulopathy?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Complement 3 Glomerulopathy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Complement 3 Glomerulopathy and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- ChemoCentryx
- Novartis Pharmaceuticals
- Omeros Corporation
- Apellis Pharmaceuticals
Key Products
- Avacopan
- Iptacopan
- OMS721
- APL-2
Table of Contents
IntroductionExecutive Summary
Complement 3 Glomerulopathy: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Iptacopan: Novartis
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Complement 3 Glomerulopathy Key Companies
Complement 3 Glomerulopathy Key Products
Complement 3 Glomerulopathy- Unmet Needs
Complement 3 Glomerulopathy- Market Drivers and Barriers
Complement 3 Glomerulopathy- Future Perspectives and Conclusion
Complement 3 Glomerulopathy Analyst Views
Complement 3 Glomerulopathy Key Companies
AppendixList of Tables
Table 1 Total Products for Complement 3 Glomerulopathy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Complement 3 Glomerulopathy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- ChemoCentryx
- Novartis Pharmaceuticals
- Omeros Corporation
- Apellis Pharmaceuticals
